Statera BioPharma (Statera BioPharma) Inventory-to-Revenue : 0.00 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Statera BioPharma's Average Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil. Statera BioPharma's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

Statera BioPharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 stayed the same from Jun. 2022 (0.00) to Jun. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Statera BioPharma's Days Inventory for the three months ended in Sep. 2022 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Statera BioPharma Inventory-to-Revenue Historical Data

The historical data trend for Statera BioPharma's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Inventory-to-Revenue Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

Inventory-to-Revenue

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Inventory-to-Revenue	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Statera BioPharma's Inventory-to-Revenue

For the Biotechnology subindustry, Statera BioPharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Inventory-to-Revenue falls into.

Statera BioPharma Inventory-to-Revenue Calculation

Statera BioPharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

	Inventory-to-Revenue (A: Dec. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

Statera BioPharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

	Inventory-to-Revenue (Q: Sep. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Sep. 2022 ))	/	count )	/	Revenue (Q: Sep. 2022 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

Statera BioPharma (OTCPK:STAB) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Statera BioPharma's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2022 )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
	=	0	/	0.169	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Statera BioPharma's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2022 )	/	Average Total Inventories (Q: Sep. 2022 )
	=	0.169	/	0
	=

Statera BioPharma Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (Statera BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Executives

Satishchandran Chandrasekhar	director	167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka	director, officer: Chief Operating Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit	officer: Chief Technology Officer	C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M.	officer: Chief Legal Officer	2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky	officer: Chief Medical Officer	2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam	officer: Chief Financial Officer	2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick	director	TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh	officer: Vice President of Finance	C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin	director	73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo	officer: Principal Financial Officer	73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin	director	73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy	director	73 HIGH STREET, BUFFALO NY 14203
Lea Verny	director	73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev	director	73 HIGH STREET, BUFFALO NY 14203